UNH Stock Analysis: UnitedHealth | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 327.802m USD | 12M Return: 6.1% | US91324P1021 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.82B
EPS Trend: -71.7%
Qual. Beats: 2
Rev. Trend: 99.3%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
UnitedHealth Group (NYSE: UNH) is a U.S.-based health care company operating across four business segments organized under two main platforms: Optum (Optum Health, Optum Insight, and Optum Rx) and UnitedHealthcare. The company is a vertically integrated player in the managed care sector, pairing health plan administration and insurance products with its own pharmacy benefit management, care delivery, and health care analytics businesses. UNH is one of the largest constituents of the GICS Managed Health Care sub-industry.
The three Optum segments handle care delivery and consumer engagement (Optum Health), software, consulting and outsourcing for providers, plans and life sciences firms (Optum Insight), and pharmacy care services including retail network contracting, home delivery, specialty pharmacy, infusion, and clinical programs such as formulary management and drug therapy management (Optum Rx).
The UnitedHealthcare segment sells consumer-oriented health benefit products and serves national, mid-sized and small employers, as well as individuals and public-sector clients. Its offerings include Medicaid managed care products (such as TANF, CHIP, DSNPs and Aged, Blind, and Disabled programs) and other state and community programs aimed at economically disadvantaged and medically underserved populations.
UnitedHealth Group was founded in 1974 and is headquartered in Eden Prairie, Minnesota. Its common stock trades on the NYSE under the ticker UNH and is classified as a mega-cap security within the Health Care sector.
- Optum Health expands care delivery and value-based contracts
- Optum Rx pharmacy margins pressured by GLP-1 drug costs
- Medicare Advantage Star ratings drive UnitedHealthcare enrollment and revenue
| Net Income: 14.1b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.56 > 1.0 |
| NWC/Revenue: -5.55% < 20% (prev -4.04%; Δ -1.51% < -1%) |
| CFO/TA 0.09 > 3% & CFO 27.0b > Net Income 14.1b |
| Net Debt (41.9b) to EBITDA (25.8b): 1.62 < 3 |
| Current Ratio: 0.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (906.0m) vs 12m ago -0.44% < -2% |
| Gross Margin: 22.49% > 18% (prev 20.84%; Δ 1.64% > 0.5%) |
| Asset Turnover: 145.6% > 50% (prev 137.0%; Δ 8.58% > 0%) |
| Interest Coverage Ratio: 5.52 > 6 (EBIT TTM 21.5b / Interest Expense TTM 3.89b) |
| A: -0.08 (Total Current Assets 86.9b - Total Current Liabilities 112b) / Total Assets 310b |
| B: 0.33 (Retained Earnings 101b / Total Assets 310b) |
| C: 0.07 (EBIT TTM 21.5b / Avg Total Assets 309b) |
| D: 0.48 (Book Value of Equity 98.4b / Total Liabilities 204b) |
| Altman-Z'' = 1.51 = BB |
| DSRI: 0.82 (Receivables 46.3b/52.7b, Revenue 450b/423b) |
| GMI: 0.93 (GM 20.84% / 22.49%) |
| AQI: 1.04 (AQ_t 0.68 / AQ_t-1 0.66) |
| SGI: 1.06 (Revenue 450b / 423b) |
| TATA: -0.04 (NI 14.1b - CFO 27.0b) / TA 310b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of October 08, 2026, the stock is trading at USD 375.98 with a total of 5,631,976 shares traded. Over the past week, the price has changed by +2.42%, over one month by -5.62%, over three months by -11.65% and over the past year by +6.14%.
Current recommended Stop Loss: 365.90 (which is 2.7% or 1.2 ATR below the current price).
UnitedHealth has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy UNH.
- StrongBuy: 15
- Buy: 7
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 481.7 | 28.1% |
P/E Trailing = 23.5917
P/E Forward = 16.5837
P/S = 0.7276
P/B = 3.4004
P/EG = 1.0118
Revenue TTM = 450b USD
EBIT TTM = 21.5b USD
EBITDA TTM = 25.8b USD
Long Term Debt = 69.5b USD (from longTermDebt, last quarter)
Short Term Debt = 3.83b USD (from shortTermDebt, last quarter)
Debt = 73.3b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 41.9b USD (calculated: Debt 73.3b - CCE 31.5b)
Enterprise Value = 370b USD (328b + Debt 73.3b - CCE 31.5b)
Interest Coverage Ratio = 5.52 (Ebit TTM 21.5b / Interest Expense TTM 3.89b)
EV/FCF = 15.65x (Enterprise Value 370b / FCF TTM 23.6b)
FCF Yield = 6.39% (FCF TTM 23.6b / Enterprise Value 370b)
FCF Margin = 5.25% (FCF TTM 23.6b / Revenue TTM 450b)
Net Margin = 3.14% (Net Income TTM 14.1b / Revenue TTM 450b)
Gross Margin = 22.49% ((Revenue TTM 450b - Cost of Revenue TTM 349b) / Revenue TTM)
Gross Margin QoQ = 32.74% (prev 22.74%)
Tobins Q-Ratio = 1.19 (Enterprise Value 370b / Total Assets 310b)
Interest Expense / Debt = 5.31% (Interest Expense 3.89b / Debt 73.3b)
Taxrate = 14.50% (2.53b / 17.4b)
NOPAT = 18.4b (EBIT 21.5b * (1 - 14.50%))
Current Ratio = 0.78 (Total Current Assets 86.9b / Total Current Liabilities 112b)
Debt / Equity = 0.74 (Debt 73.3b / totalStockholderEquity, last quarter 98.4b)
Debt / EBITDA = 1.62 (Net Debt 41.9b / EBITDA 25.8b)
Debt / FCF = 1.77 (Net Debt 41.9b / FCF TTM 23.6b)
Total Stockholder Equity = 96.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.57% (Net Income 14.1b / Total Assets 310b)
RoE = 14.63% (Net Income TTM 14.1b / Total Stockholder Equity 96.6b)
RoCE = 12.93% (EBIT 21.5b / Capital Employed (Equity 96.6b + L.T.Debt 69.5b))
RoIC = 10.25% (NOPAT 18.4b / Invested Capital 179b)
WACC = 5.48% (E(328b)/V(401b) * Re(5.69%) + D(73.3b)/V(401b) * Rd(5.31%) * (1-Tc(0.14)))
Discount Rate = 5.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -87.51 | Cagr: -0.78%
[DCF] Terminal Value 74.51% ; FCFF base≈24.3b ; Y1≈23.0b ; Y5≈21.8b
[DCF] Fair Price = 335.9 (EV 343b - Net Debt 41.9b = Equity 302b / Shares 897.6m; r=8.35% [WACC [floored]]; 5y FCF grow -6.55% → 2.50% )
EPS Correlation: -71.65 | EPS CAGR: -14.66% | SUE: 4.0 | # QB: 2
Revenue Correlation: 99.25 | Revenue CAGR: 9.02% | SUE: 0.93 | # QB: 2
EPS current Quarter (2026-09-30): EPS=4.15 | Chg30d=+0.75% | Revisions=+38% | Analysts=23
EPS current Year (2026-12-31): EPS=19.87 | Chg30d=+0.28% | Revisions=+57% | GrowthEPS=+21.5% | GrowthRev=-0.1%
EPS next Year (2027-12-31): EPS=22.61 | Chg30d=+0.78% | Revisions=+44% | GrowthEPS=+13.8% | GrowthRev=+2.9%
[Analyst] Revisions Ratio: +61% (up=13, down=2)